RNS Number:0269Q
British Biotech PLC
22 September 2003


                                  SCHEDULE 10

                   NOTIFICATION OF MAJOR INTERESTS IN SHARES


1. Name of company

British Biotech plc

2. Name of shareholder having a major interest

FMR Corp and its direct and indirect subsidiaries; and Fidelity Investment Ltd
and its direct and indirect subsidiaries

3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18

Notification indicates that it is in respect of a non-beneficial interest.

4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them

Mellon Bank                     185,647
Chase Manhatten Bank London   6,249,853
HSBC                            267,072
Chase Manhatten Bank London     609,276
State Street Bank & Trust        53,382

5. Number of shares / amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares / amount of stock disposed

n/a

8. Percentage of issued class

n/a

9. Class of security

Ordinary 5p shares

10. Date of transaction

n/a

11. Date company informed

22 September, 2003

12. Total holding following this notification

7,365,230

13. Total percentage holding of issued class following this notification

5.47 per cent (based on issued shared capital of 134,694,961 shares at 22
September 2003)

14. Any additional information

Notification is in respect of acquisition of British Biotech shares following
the merger of British Biotech pc and Vernalis Group plc.

15. Name of contact and telephone number for queries

Tony Weir + 44 1 865 781166

16. Name and signature of authorised company official responsible for making
this notification

Tony Weir, Finance Director

Date of notification

22 September, 2003


The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
HOLLTMATMMJTBJJ